FDA Submission Strategy Consulting

Submission strategy shapes everything downstream

Pathway selection, predicate strategy, testing scope, and FDA interaction planning determine submission timelines and risk long before content is drafted. Early strategic decisions are usually the cheapest place to prevent later delays.

Common FDA strategy support areas

• Regulatory pathway assessment (510(k), De Novo, PMA)
• Predicate device identification and comparison strategy
• Pre-Submission (Q-Sub) planning and FDA meeting preparation
• Testing and evidence planning aligned to FDA expectations
• Submission timeline and risk planning
• Response strategy for FDA questions and deficiencies

Experienced strategy input without permanent headcount

EZ Regulatory supports MedTech teams that need experienced FDA strategy input at decision points — before submission work locks in cost and timeline.

Common questions

What is an FDA submission strategy?

An FDA submission strategy defines the regulatory pathway, predicate or classification approach, required evidence, FDA interaction plan, and submission timeline for a medical device before detailed submission work begins.

When should a company define its FDA strategy?

As early as possible — ideally during design and development planning. Pathway and evidence decisions made early determine testing scope, budget, and time to market.

What FDA pathways exist for medical devices?

Most devices reach the US market through 510(k) clearance, De Novo classification, or PMA approval. The right pathway depends on device risk, novelty, and available predicates.